Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Executive Summary

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies. 

You may also be interested in...



Immunocore Expects EU Verdict This Week On Novel TCR Immunotherapy

Pfizer’s oral COVID-19 antiviral drug and Celgene/Bristol Myers Squibb’s CAR-T for treating large B-cell lymphoma are among 11 new drugs on which the EMA is set to adopt recommendations on their possible EU-wide approval.

Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus

The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.

China-Only Studies Are ‘Problematic,’ US FDA’s Pazdur Says Ahead Of Lilly/Innovent PD-1 Inhibitor Review

February advisory committee for sintilimab expected to address three main questions about applications relying on single-country data.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel